{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:28:49Z","timestamp":1790659729264,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40257-021-00643-2","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T06:02:36Z","timestamp":1636437756000},"page":"69-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-5270","authenticated-orcid":false,"given":"Valerie D.","family":"Callender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran E.","family":"Cook-Bolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"issue":"1","key":"643_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40257-013-0049-1","volume":"15","author":"NC Yin","year":"2014","unstructured":"Yin NC, McMichael AJ. Acne in patients with skin of color: practical management. Am J Clin Dermatol. 2014;15(1):7\u201316.","journal-title":"Am J Clin Dermatol"},{"issue":"3s","key":"643_CR2","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.12788\/j.sder.2018.027","volume":"37","author":"AF Alexis","year":"2018","unstructured":"Alexis AF, Harper JC, Stein Gold LF, Tan JKL. Treating acne in patients with skin of color. Semin Cutan Med Surg. 2018;37(3s):S71\u20133.","journal-title":"Semin Cutan Med Surg"},{"key":"643_CR3","volume-title":"Postinflammatory hyperpigmentation","author":"E Lawrence","year":"2020","unstructured":"Lawrence E, Al Aboud KM. Postinflammatory hyperpigmentation. Treasure Island: StatPearls; 2020."},{"issue":"4","key":"643_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40257-017-0333-6","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Aman T, Alexis AF. Postinflammatory hyperpigmentation: epidemiology, clinical presentation, pathogenesis and treatment. Am J Clin Dermatol. 2018;19(4):489\u2013503.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"643_CR5","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"key":"643_CR6","doi-asserted-by":"crossref","unstructured":"Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2)(Suppl 2):S98-106.","DOI":"10.1067\/mjd.2002.120791"},{"issue":"8","key":"643_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-4362.1992.tb02717.x","volume":"31","author":"G Chua-Ty","year":"1992","unstructured":"Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989\u20131990. Int J Dermatol. 1992;31(8):555\u20139.","journal-title":"Int J Dermatol"},{"issue":"9","key":"643_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1468-3083.2010.03919.x","volume":"25","author":"AC Perkins","year":"2011","unstructured":"Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25(9):1054\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"643_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JDN.0000000000000129","volume":"7","author":"J Gorelick","year":"2015","unstructured":"Gorelick J, Daniels SR, Kawata AK, Degboe A, Wilcox TK, Burk CT, et al. Acne-related quality of life among female adults of different races\/ethnicities. J Dermatol Nurses Assoc. 2015;7(3):154\u201362.","journal-title":"J Dermatol Nurses Assoc."},{"issue":"7","key":"643_CR10","first-page":"19","volume":"7","author":"VD Callender","year":"2014","unstructured":"Callender VD, Alexis AF, Daniels SR, Kawata AK, Burk CT, Wilcox TK, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"7","key":"643_CR11","first-page":"716","volume":"20","author":"AF Alexis","year":"2021","unstructured":"Alexis AF, Woolery-Lloyd H, Williams K, Andriessen A, Callender VD, Kang S, et al. Racial\/ethnic variations in acne: implications for treatment and skin care recommendations for acne patients with skin of color. J Drugs Dermatol. 2021;20(7):716\u201325.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"643_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u201373 e33.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"643_CR13","first-page":"s51","volume":"17","author":"A Chien","year":"2018","unstructured":"Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12):s51\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"643_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","volume":"7","author":"J Leyden","year":"2017","unstructured":"Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293\u2013304.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"643_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.36849\/JDD.2020.5125","volume":"19","author":"N Bhatia","year":"2020","unstructured":"Bhatia N, Weiss JS, Sadick N, Cook-Bolden FE, Tyring SK, Guenin E, et al. Novel polymeric tazarotene 0.045% lotion for moderate-to-severe acne: pooled phase 3 analysis by race\/ethnicity. J Drugs Dermatol. 2020;19(7):727\u201334.","journal-title":"J Drugs Dermatol"},{"key":"643_CR16","unstructured":"Cook-Bolden FE, Bhatia N, Alexis AF, Green L, Stein Gold L, Han G, et al. Polymeric emulsion tazarotene 0.045% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in Asian participants [poster]. In: Presented virtually at the Skin of Color Society annual scientific symposium, August 31, 2021."},{"issue":"1","key":"643_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12788\/cutis.0059","volume":"106","author":"ND Bhatia","year":"2020","unstructured":"Bhatia ND, Werschler WP, Cook-Bolden FE, Guenin E. Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc analysis in a black population. Cutis. 2020;106(1):45\u201350.","journal-title":"Cutis"},{"issue":"9","key":"643_CR18","first-page":"910","volume":"18","author":"G Han","year":"2019","unstructured":"Han G, Armstrong AW, Desai SR, Guenin E. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in an Asian population. J Drugs Dermatol. 2019;18(9):910\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"643_CR19","first-page":"32","volume":"18","author":"FE Cook-Bolden","year":"2019","unstructured":"Cook-Bolden FE, Weinkle SH, Guenin E, Bhatt V. Novel tretinoin 0.05% lotion for once-daily treatment of moderate-to-severe acne vulgaris in a Hispanic population. J Drugs Dermatol. 2019;18(1):32\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"643_CR20","first-page":"25","volume":"5","author":"VD Callender","year":"2012","unstructured":"Callender VD, Young CM, Kindred C, Taylor SC. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25\u201332.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"5","key":"643_CR21","first-page":"549","volume":"9","author":"E Tanghetti","year":"2010","unstructured":"Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549\u201358.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"643_CR22","first-page":"365","volume":"81","author":"FE Cook-Bolden","year":"2008","unstructured":"Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis. 2008;81(4):365\u201371.","journal-title":"Cutis"},{"issue":"1","key":"643_CR23","first-page":"45","volume":"77","author":"P Grimes","year":"2006","unstructured":"Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45\u201350.","journal-title":"Cutis"},{"issue":"6","key":"643_CR24","first-page":"362","volume":"74","author":"PE Grimes","year":"2004","unstructured":"Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74(6):362\u20138.","journal-title":"Cutis"},{"issue":"Suppl 3","key":"643_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.0926-9959.2001.00011.x","volume":"15","author":"WK Jacyk","year":"2001","unstructured":"Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):37\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"643_CR26","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJM199305203282002","volume":"328","author":"SM Bulengo-Ransby","year":"1993","unstructured":"Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438\u201343.","journal-title":"N Engl J Med"},{"issue":"2 Pt 3","key":"643_CR27","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0190-9622(97)80395-7","volume":"37","author":"RA Chandraratna","year":"1997","unstructured":"Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S12\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"643_CR28","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/jid.2013.237","volume":"133","author":"CQF Wang","year":"2013","unstructured":"Wang CQF, Akalu YT, Suarez-Farinas M, Gonzalez J, Mitsui H, Lowes MA, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Investig Dermatol. 2013;133(12):2741\u201352.","journal-title":"J Investig Dermatol"},{"key":"643_CR29","unstructured":"Avage (tazrotene 0.1% cream). Prescribing information. Madison NJ: Allergan USA, Dec 2019."},{"issue":"6","key":"643_CR30","first-page":"s61","volume":"13","author":"AF Alexis","year":"2014","unstructured":"Alexis AF. Acne vulgaris in skin of color: understanding nuances and optimizing treatment outcomes. J Drugs Dermatol. 2014;13(6):s61\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"643_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-021-00594-8","volume":"22","author":"H Baldwin","year":"2021","unstructured":"Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. 50 years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315\u201327.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"643_CR32","first-page":"s148","volume":"18","author":"LH Kircik","year":"2019","unstructured":"Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):s148\u201354.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"643_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/09546634.2019.1668907","volume":"32","author":"EA Tanghetti","year":"2021","unstructured":"Tanghetti EA, Stein Gold L, Del Rosso JQ, Lin T, Angel A, Pillai R. Optimized formulation for topical application of a fixed combination halobetasol\/tazarotene lotion using polymeric emulsion technology. J Dermatol Treat. 2021;32(4):391\u20138.","journal-title":"J Dermatol Treat."},{"issue":"6","key":"643_CR34","first-page":"542","volume":"18","author":"EA Tanghetti","year":"2019","unstructured":"Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"643_CR35","first-page":"1084","volume":"17","author":"SK Tyring","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u201391.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"643_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.36849\/JDD.2020.4869","volume":"19","author":"EA Tanghetti","year":"2020","unstructured":"Tanghetti EA, Werschler WP, Lain E, Guenin E, Harris S, Loncaric A, et al. Novel polymeric lotion formulation of once-daily tazarotene (0.045%) for moderate-to-severe acne: pooled phase 3 analysis. J Drugs Dermatol. 2020;19(3):272\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"643_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.36849\/JDD.2020.3977","volume":"19","author":"EA Tanghetti","year":"2020","unstructured":"Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"643_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/1060028020934892","volume":"55","author":"KA Bell","year":"2021","unstructured":"Bell KA, Brumfiel CM, Haidari W, Boger L. Trifarotene for the treatment of facial and truncal acne. Ann Pharmacother. 2021;55(1):111\u20136.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"643_CR39","first-page":"442","volume":"179","author":"J Aubert","year":"2018","unstructured":"Aubert J, Piwnica D, Bertino B, Blanchet-Rethore S, Carlavan I, Deret S, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179(2):442\u201356.","journal-title":"Br J Dermatol"},{"key":"643_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s13671-012-0016-8","volume":"1","author":"K Zarchi","year":"2012","unstructured":"Zarchi K, Jemec GBE. Severity assessment and outcome measures in acne vulgaris. Curr Derm Rep. 2012;1:131\u20136.","journal-title":"Curr Derm Rep."},{"issue":"4","key":"643_CR41","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/bjd.14184","volume":"174","author":"P Isedeh","year":"2016","unstructured":"Isedeh P, Kohli I, Al-Jamal M, Agbai ON, Chaffins M, Devpura S, et al. An in vivo model for postinflammatory hyperpigmentation: an analysis of histological, spectroscopic, colorimetric and clinical traits. Br J Dermatol. 2016;174(4):862\u20138.","journal-title":"Br J Dermatol"},{"issue":"12","key":"643_CR42","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.12667","volume":"41","author":"CL Goh","year":"2014","unstructured":"Goh CL, Abad-Casintahan F, Chow SK, Kubba R, Miyachi Y, Noppakun N, et al. Evaluating acne-related post-inflammatory hyperpigmentation is a challenge even amongst experts. J Dermatol. 2014;41(12):1106\u20138.","journal-title":"J Dermatol"},{"issue":"1","key":"643_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaad.2013.09.017","volume":"70","author":"SA Savory","year":"2014","unstructured":"Savory SA, Agim NG, Mao R, Peter S, Wang C, Maldonado G, et al. Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris. J Am Acad Dermatol. 2014;70(1):108\u201314.","journal-title":"J Am Acad Dermatol"},{"issue":"8 Suppl","key":"643_CR44","first-page":"s109","volume":"12","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol. 2013;12(8 Suppl):s109\u201315.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"643_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1523-1747.2003.12321.x","volume":"121","author":"AH Jeremy","year":"2003","unstructured":"Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Investig Dermatol. 2003;121(1):20\u20137.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"643_CR46","first-page":"24","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24\u201338.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"3","key":"643_CR47","first-page":"119","volume":"83","author":"JQ Del Rosso","year":"2009","unstructured":"Del Rosso JQ, Lehman PA, Raney SG. Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. Cutis. 2009;83(3):119\u201324.","journal-title":"Cutis"},{"issue":"6","key":"643_CR48","first-page":"748","volume":"11","author":"JA Zeichner","year":"2012","unstructured":"Zeichner JA, Patel RV, Haddican M, Wong V. Efficacy and safety of a ceramide containing moisturizer followed by fixed-dose clindamycin phosphate 1.2%\/benzoyl peroxide 2.5% gel in the morning in combination with a ceramide containing moisturizer followed by tretinoin 0.05% gel in the evening for the treatment of facial acne vulgaris. J Drugs Dermatol. 2012;11(6):748\u201352.","journal-title":"J Drugs Dermatol"},{"key":"643_CR49","doi-asserted-by":"publisher","unstructured":"Searle T, Ali FR, Al-Niaimi F. The versatility of azelaic acid in dermatology. J Dermatol Treat. 2020:1\u201311. https:\/\/doi.org\/10.1080\/09546634.2020.1800579.","DOI":"10.1080\/09546634.2020.1800579"},{"issue":"9","key":"643_CR50","first-page":"964","volume":"14","author":"BC Schulte","year":"2015","unstructured":"Schulte BC, Wu W, Rosen T. Azelaic acid: evidence-based update on mechanism of action and clinical application. J Drugs Dermatol. 2015;14(9):964\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"643_CR51","first-page":"534","volume":"16","author":"LK Hoffman","year":"2017","unstructured":"Hoffman LK, Del Rosso JQ, Kircik LH. The efficacy and safety of azelaic acid 15% foam in the treatment of truncal acne vulgaris. J Drugs Dermatol. 2017;16(6):534\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"643_CR52","first-page":"641","volume":"17","author":"PW Hashim","year":"2018","unstructured":"Hashim PW, Chen T, Harper JC, Kircik LH. The efficacy and safety of azelaic acid 15% foam in the treatment of facial acne vulgaris. J Drugs Dermatol. 2018;17(6):641\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"643_CR53","first-page":"586","volume":"10","author":"LH Kircik","year":"2011","unstructured":"Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586\u201390.","journal-title":"J Drugs Dermatol"},{"issue":"5 Suppl","key":"643_CR54","first-page":"18","volume":"84","author":"E Tanghetti","year":"2009","unstructured":"Tanghetti E. Fixed-combination clindamycin 1%-benzoyl peroxide 5% hydrating gel: a flexible component of acne management. Cutis. 2009;84(5 Suppl):18\u201324.","journal-title":"Cutis"},{"issue":"7","key":"643_CR55","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/ijd.14761","volume":"59","author":"N Ghaoui","year":"2020","unstructured":"Ghaoui N, Hanna E, Abbas O, Kibbi AG, Kurban M. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787\u201395.","journal-title":"Int J Dermatol"},{"issue":"2","key":"643_CR56","first-page":"160","volume":"17","author":"SC Taylor","year":"2018","unstructured":"Taylor SC, Cook-Bolden FE, McMichael A, Downie JB, Rodriguez DA, Alexis AF, et al. Efficacy, safety, and tolerability of topical dapsone gel, 7.5% for treatment of acne vulgaris by fitzpatrick skin phototype. J Drugs Dermatol. 2018;17(2):160\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"643_CR57","first-page":"718","volume":"18","author":"KA Huerth","year":"2019","unstructured":"Huerth KA, Hassan S, Callender VD. Therapeutic insights in melasma and hyperpigmentation management. J Drugs Dermatol. 2019;18(8):718\u201329.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"643_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13555-020-00481-w","volume":"11","author":"JJ Han","year":"2021","unstructured":"Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. New acne therapies and updates on use of spironolactone and isotretinoin: a narrative review. Dermatol Ther. 2021;11(1):79\u201391.","journal-title":"Dermatol Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00643-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00643-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:38:10Z","timestamp":1675877890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00643-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00643-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"28 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing support for this review article was funded by Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Valerie Callender has served as an investigator, consultant, or speaker for AbbVie, Beiersdorf, Eli Lilly, Galderma, InCyte, L\u2019Or\u00e9al, Ortho Dermatologics, Pfizer, Revance, Sente Labs, UCB and Vyne. Hilary Baldwin has served as advisor, investigator, and on speakers\u2019 bureaus for Almirall, Cassiopea, Vyne, Galderma, Ortho Dermatologics, Sol Gel, and Sun Pharma. Fran Cook-Bolden has served as consultant, speaker, investigator for Galderma, LEO Pharma, Almirall, Cassiopea, Ortho Dermatologics, Investigators Encore, Foamix, Hovione, Aclaris, Cutanea. Andrew Alexis has received grant\/research support (funds to institution) from Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis; has served as a consultant\/advisory board member for Leo, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L\u2019Oreal, BMS, Menlo, Scientis, Bausch Health, UCB, Vyne, Cassiopea, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen; and has served as a speaker for Pfizer, Sanofi-Genzyme\/Regeneron, Astra Zeneca. Linda Stein Gold has served as an investigator\/consultant or speaker for Ortho Dermatologics, LEO Pharma, Dermavant, Incyte, Novartis, AbbVie, Pfizer, Sun Pharma, UCB, Arcutis, Vyne, Sol-Gel, and Lilly. Eric Guenin is an employee of Ortho Dermatologics and may hold stock and\/or stock options in its parent company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Patients provided written informed consent for photographs to be used for educational purposes.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"All authors made substantial contributions to the conception and design of the work; drafted the work\/revised it critically; approved the version to be published; and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}